Drugs / DBM-1152A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07439419 | Aug → Oct 2024 | — | Joincare Pharmaceutical Group Industry Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT07447141 | Dec 2023 → Apr 2024 | — | Joincare Pharmaceutical Group Industry Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DBM-1152A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07439419 ↗ |
| Route | Inhaled | “DBM-1152A and placebo will be administered by nebulized inhalation once daily for 7 consecutive days.” NCT07439419 ↗ |